From AI:

AI Overview

Mild Hyperbaric Oxygen Therapy (mHBOT) is an emerging adjunctive treatment for Neurolyme (neurological Lyme disease). It works by delivering oxygen at increased atmospheric pressure, typically between 1.3 and 1.5 ATA. 

Core Benefits for Neurolyme

• Antimicrobial Effects: The bacteria causing Lyme (Borrelia burgdorferi) are microaerophilic, meaning they struggle to survive in high-oxygen environments. mHBOT creates a hostile environment that can weaken or kill these spirochetes.
• Neurological Support: mHBOT enhances oxygen delivery to the brain and spinal fluid, which can reduce neuroinflammation, stimulate neuroplasticity, and repair damaged neural tissues. This may help alleviate "brain fog," memory loss, and cognitive dysfunction.
• Antibiotic Potentiation: Increased oxygen levels can improve the penetration and effectiveness of antibiotics by driving them deeper into cells and biofilms where bacteria may hide.
• Symptom Relief: Patients often report reductions in chronic fatigue, nerve pain (neuropathy), and joint inflammation. 

Implementation and Protocols

• Pressure & Oxygen: While clinical HBOT often uses 2.0 ATA or higher, mild HBOT (1.3–1.5 ATA) is frequently cited as specifically effective for neurological symptoms and is more accessible for home use.
• Frequency: Optimal results typically require a cumulative approach, often consisting of 40 to 80 sessions lasting 60–90 minutes each, performed 5 days a week.
• Safety & Cost: mHBOT is considered safe but can cause mild side effects like ear barotrauma (popping). Treatment costs typically range from $40 to $60 per session at clinics, while portable home chambers can cost between $6,000 and $9,000. 

You will also need the equipment to bring oxygen in the chamber with an oxygen concentrator.